A new study in the UK will investigate the long-term effects of lung inflammation and scarring from COVID-19, Imperial College London announced on Wednesday.
After battling COVID-19, many patients experience long-term symptoms of lung damage, including breathlessness, coughing, fatigue and limited ability to exercise.
The inflammation in the lungs may improve over time, but in some people it persists and in severe cases the lungs may become scarred, Imperial explained.
Supported by GBP2m of funding from UK Research and Innovation (UKRI), the researchers at Imperial aim to develop treatment strategies to prevent the development of severe scarring and disability following COVID-19.
(USD1=GBP0.73)
FDA grants rare paediatric disease designation to RedHill's opaganib
Antengene presents first ATG-207 preclinical data at EULAR 2026
Gilead and Lakefront complete Ouro Medicines acquisition to expand autoimmune disease pipeline
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
UCB launches scholarship program for adults living with hidradenitis suppurativa
Upsher-Smith launches generic Cyclosporine Ophthalmic Emulsion 0.05%
Accro Bioscience completes USD50m Series C financing
Atisama Therapeutics reports progress in Phase 1 study of RB042
Mabwell's clinical trial application for 9MW5211 cleared by US FDA